New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

OhhMed Medical Ltd., a pioneering medical technology firm specialising in male urology, today announced the initiation of a ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.

SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial ...

(Reuters Health) - - In men with localized prostate cancer discovered because they had symptoms or noticed during a work-up for another medical problem, radical prostate surgery leads to an average of ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

At 24 months' follow-up, the only phase 3 randomized clinical trial to directly compare functional and oncologic outcomes between robot-assisted laparoscopic prostatectomy and open radical retropubic ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients. Prostate cancer treatment continues to evolve, and ...